193 completed, 93 recruiting, 89 terminated, 48 active not recruiting. 248 Phase 2, 178 Phase 1, 77 Phase 3, 4 Early Phase 1, 3 Not applicable.
Follow Incyte Corporation: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML Decitabine, Venetoclax, Axatilimab - Acute Myeloid Leukemia, TP53 Gene Mutation | Phase 1 | Not yet recruiting | Northside Hospital, Inc. | 32 | 2027-01-31 | 2026-10-16 |
| Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC vilastobart (XTX101), Retifanlimab - Pancreatic Cancer Metastatic | Phase 2 | Not yet recruiting | Massachusetts General Hospital | 40 | 2027-01-01 | 2026-08-14 |
| A Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma With FGFR2 Fusion or Rearrangements After at Least 1 Prior Line of Systemic Therapy Pemigatinib - Unresectable Cholangiocarcinoma, Advanced/Metastatic Cholangiocarcinoma | Phase 2 | Not yet recruiting | Incyte Corporation | 72 | 2026-12-15 | 2026-10-20 |
| Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1 INCB123667, Bevacizumab, Placebo - Ovarian Cancer | Phase 3 | Not yet recruiting | Incyte Corporation | 590 | 2026-12-01 | 2026-10-02 |
| TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma Tafasitamab, Polatuzumab vedotin, Glofitamab - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 2 | Not yet recruiting | Brown University | 30 | 2026-11-01 | 2026-09-01 |
| Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Ampulla of Vater Carcinoma, Locally Advanced Biliary Tract Carcinoma | Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 29 | 2026-11-01 | 2026-09-10 |
| A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection and Chemotherapy INCA33890 - CRC (Colorectal Cancer) | Phase 2 | Not yet recruiting | Incyte Corporation | 40 | 2026-10-26 | 2026-09-22 |
| A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Impaired Renal Function and Participants on Hemodialysis INCB161734 - Renal Insufficiency, Kidney Diseases | Phase 1 | Not yet recruiting | Incyte Corporation | 24 | 2026-10-26 | 2026-10-02 |
| A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Hepatic Impairment INCB161734 - Hepatic Insufficiency, Liver Diseases | Phase 1 | Not yet recruiting | Incyte Corporation | 24 | 2026-10-13 | 2026-10-01 |
| Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma Rituximab, Tafasitamab, Biospecimen Collection - Classic Follicular Lymphoma, Grade 1 Follicular Lymphoma | Phase 2 | Recruiting | University of Washington | 30 | 2026-10-09 | 2026-10-15 |
| A Study to Assess the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB161734 in Healthy Male Participants INCB161734 - Healthy Participants | Phase 1 | Active not recruiting | Incyte Corporation | 10 | 2026-09-18 | 2026-10-14 |
| A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia INCA033989, Best Available Treatment - Essential Thrombocythemia | Phase 3 | Recruiting | Incyte Corporation | 426 | 2026-09-08 | 2026-10-15 |
| Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Allogeneic NK cells, Rituximab, Tafasitamab - Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma | Phase 1 | Recruiting | Paolo Caimi, MD | 15 | 2026-09-01 | 2026-09-09 |
| Topical Ruxolitinib in the Treatment of Adults With Pyoderma Gangrenosum topical ruxolitinib 1.5% cream - Pyoderma Gangrenosum | Phase 2 | Recruiting | Oregon Health and Science University | 12 | 2026-09-01 | 2026-10-09 |
| Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE) Ruxolitinib - Immune Effector Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS) | Phase 1 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 16 | 2026-07-15 | 2026-07-28 |
| ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer HPV ctDNA Response based radiation, Chemotherapy, Retifanlimab - Anal Cancer, HPV-Related Carcinoma | Phase 2 | Recruiting | Jennifer Dorth | 33 | 2026-06-19 | 2026-08-14 |
| Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease Ruxolitinib - Sickle Cell Disease, Hematopoetic Stem Cell Transplant | Phase 1 / Phase 2 | Recruiting | Arkansas Children's Hospital Research Institute | 24 | 2026-06-08 | 2026-06-04 |
| Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer Biopsy, Biospecimen Collection, Bone Scan - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 20 | 2026-06-01 | 2026-05-05 |
| ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation Pembrolizumab, Radiotherapy, Axatilimab - TNBC - Triple-Negative Breast Cancer, Breast Cancer | Phase 2 | Not yet recruiting | Stephen Shiao | 34 | 2026-06-01 | 2026-04-20 |
| A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease INCB123667 - Renal Impairment | Phase 1 | Recruiting | Incyte Corporation | 16 | 2026-05-29 | 2026-06-16 |
Showing 20 of 466. Sign in to see all of them.
Primary Myelofibrosis (36) · Myeloproliferative Disorders (30) · Carcinoma, Non-Small-Cell Lung (26) · Dermatitis, Atopic (24) · Lymphoma (20) · Lymphoma, Large B-Cell, Diffuse (20) · Colorectal Neoplasms (19) · Bronchiolitis Obliterans Syndrome (18) · Eczema (18) · Breast Neoplasms (17) · Melanoma (16) · Pancreatic Neoplasms (16) · Lymphoma, Non-Hodgkin (15) · Neoplasm Metastasis (15) · Ovarian Neoplasms (15)
ruxolitinib (130) · itacitinib (40) · epacadostat (39) · INCB039110 (32) · parsaclisib (27) · pembrolizumab (26) · pemigatinib (26) · tafasitamab (24) · baricitinib (22) · Cyclophosphamide (19) · Lenalidomide (18) · Gemcitabine (17) · Rituximab (17) · axatilimab (16) · Specimen Handling (15)
United States (400) · Spain (107) · Italy (103) · France (95) · Germany (93) · Canada (92) · United Kingdom (87) · Poland (69) · Belgium (65) · Japan (58) · Australia (57) · Austria (44) · Netherlands (43) · South Korea (43) · Denmark (38)
Kathleen Butler, MD (12) · Peter Langmuir, MD (9) · Mark Jones, MD (8) · Lance Leopold, MD (7) · Albert Assad, MD (6) · Fred Zheng, MD (6) · Haq Nawaz, MD (6) · Rodica Morariu-Zamfir, MD (6) · Fitzroy Dawkins, MD (4) · William V Williams, MD (4)
PMID 33826132, PMID 36255569, PMID 36749121, PMID 33658996, PMID 33982267, PMID 34275122, PMID 34688290, PMID 41125994, PMID 29316837, PMID 29463520, PMID 29508247, PMID 30842122, PMID 31527168, PMID 33222559, PMID 33687069, PMID 33899152, PMID 33957195, PMID 34706874, PMID 34978076, PMID 35334197, PMID 35689489, PMID 36260792, PMID 36264430, PMID 36763878, PMID 36855020, PMID 37381691, PMID 37556146, PMID 37991697, PMID 38698175, PMID 38904749, PMID 39375281, PMID 39462179, PMID 39546129, PMID 40156697, PMID 40214720, PMID 40305472, PMID 41180818, PMID 41678112, PMID 42201333, PMID 42493571, PMID 42580817, PMID 42825995, PMID 15466922, PMID 15661029, PMID 20049711, PMID 20413513, PMID 20602996, PMID 20843246, PMID 20876310, PMID 21654748
2017 (29), 2023 (20), 2018 (14), 2016 (9), 2019 (9), 2025 (5), P01CA108671 (2), P50CA062924 (2), 2008 (1), 2014 (1), 2015 (1), K12CA167540 (1), P01CA039542 (1), P01CA247886 (1), P30CA015704 (1)